T98G-luc Orthotopic Mouse Model Service for Brain Cancer

The T98G-luc orthotopic mouse model for brain cancer represents a robust, MGMT-expressing human glioblastoma xenograft platform uniquely suited for evaluating alkylating agent resistance and blood-brain barrier–penetrant therapeutics in an anatomically faithful intracranial setting. Alfa Cytology delivers a comprehensive preclinical service for this model, spanning luciferase-stable cell line sourcing, Matrigel-assisted stereotactic intracranial implantation, serial bioluminescence imaging, and detailed neuropathological endpoint analysis to advance your glioblastoma drug discovery and resistance-overcoming strategies.

Overview of T98G-luc Orthotopic Mouse Model for Brain Cancer

The T98G-luc orthotopic brain tumor model is generated by stereotactic injection of luciferase-transduced human T98G glioblastoma cells into the frontal lobe striatum of immunodeficient mice, creating a human-derived xenograft that recapitulates the aggressive growth, pseudopalisading necrosis, and microvascular proliferation characteristic of patient glioblastoma multiforme. Originally established in 1979 by Stein from a 61-year-old Caucasian male patient, the T98G line is distinguished by its hyperpentaploid karyotype, fibroblast-like morphology, and unique capacity to enter a viable G1-arrested state under stationary-phase conditions—properties that set it apart from other glioblastoma cell lines and make it an exceptional model for studying cell cycle regulation alongside tumor progression. The stable integration of firefly luciferase enables quantitative, noninvasive bioluminescence imaging across the disease trajectory, allowing researchers to monitor tumor engraftment kinetics, assess therapeutic response longitudinally, and capture early signs of treatment failure with high sensitivity.

Fig 1. BLI imaging of glioma in situ (Day 5 vs Day 26). (Luwor, Rodney B., et al., 2015)

From a molecular perspective, T98G harbors a missense mutation in TP53 codon 237 (Met→Ile transition), exhibits robust PTEN expression with an unmethylated promoter, and displays high-level MGMT expression driven by promoter methylation—a profile that confers pronounced resistance to temozolomide and positions this model as an ideal preclinical tool for testing alkylating-agent sensitization strategies, DNA repair inhibitors, and combination regimens. When implanted orthotopically with Matrigel as a supportive extracellular matrix scaffold, T98G cells achieve 100% engraftment at standard doses, forming tumors that exhibit dense sheets of poorly differentiated glial-like cells, brisk mitotic activity, and perivascular cuffing. This model thereby provides a translationally faithful testing ground for evaluating blood-brain barrier–penetrant small molecules, nanoparticle drug delivery systems, radiation sensitizers, and targeted agents directed at the PI3K/AKT/mTOR, MEK, and BCL-2 survival pathways.

Cell Line Information: T98G-luc

The T98G-luc cell line is a human glioblastoma multiforme line engineered to stably express firefly luciferase, enabling sensitive, ATP-dependent bioluminescent detection in living animals. The parental T98G line was originally established in 1979 by G.H. Stein from a glioblastoma multiforme tumor resected from the brain of a 61-year-old Caucasian male patient. Below is a comprehensive summary of the key characteristics of the T98G parental and T98G-luc reporter cell lines:

Our Services

Alfa Cytology provides an end-to-end T98G-luc orthotopic glioblastoma model service engineered to address the specific challenges of alkylating-agent resistance and blood-brain barrier drug delivery in high-grade glioma. Our capabilities encompass luciferase-stable cell line qualification, Matrigel-assisted stereotactic intracranial implantation, scheduled bioluminescence imaging sessions, and comprehensive histopathological and molecular endpoint characterization—delivering reproducible, publication-quality data that de-risks your therapeutic pipeline from mechanistic validation through candidate selection.

Workflow of T98G-luc Orthotopic Mouse Model Construction

Construction of the T98G-luc orthotopic brain tumor model employs a Matrigel-assisted stereotactic intracranial injection protocol optimized to overcome the inherent non-tumorigenicity of T98G in immunodeficient hosts and achieve reliable tumor engraftment with minimal perioperative mortality. The workflow integrates extracellular matrix scaffolding, neurosurgical precision, longitudinal BLI monitoring, and rigorous endpoint analysis to generate a robust preclinical glioblastoma platform. The essential steps are outlined below:

1. Cell Preparation and Matrigel Formulation: T98G-luc cells are expanded under standard culture conditions and harvested during logarithmic growth phase. Cell viability is confirmed by trypan blue exclusion (target >95% viability), and luciferase expression is validated by in vitro luciferase assay. For inoculation, cells are resuspended in ice-cold serum-free medium and mixed 1:1 with phenol red–free, growth factor–reduced Matrigel to a final concentration of 4×10⁴ to 1×10⁵ cells per 10 µL. The Matrigel–cell suspension is kept on ice until injection to prevent premature polymerization.
2. Preoperative Preparation and Anesthesia: Female athymic nude mice or NOD-SCID mice (6–8 weeks old, ~20–22 g) are acclimatized for at least one week. On the day of surgery, mice are anesthetized with isoflurane (3–4% induction, 1.5–2% maintenance in medical oxygen) or an intraperitoneal ketamine/xylazine cocktail. The scalp is shaved and sterilized with alternating povidone-iodine and 70% ethanol. Body temperature is maintained on a heated surgical platform throughout the procedure.
3. Stereotactic Cranial Exposure: A midline scalp incision is made to expose the cranium, and bregma is identified as the stereotactic zero reference. A dental drill creates a burr hole at the following coordinates relative to bregma: anterior–posterior +0.5 mm, medial–lateral −2.0 to −2.5 mm (right frontal lobe). The dura mater is gently perforated with a fine needle to permit smooth passage of the injection cannula.
4. Intracranial Cell–Matrigel Inoculation: A 26-gauge Hamilton syringe mounted on a stereotactic frame is lowered through the burr hole to a depth of 2.5–3.0 mm below the dura mater (frontal lobe striatum target). The ice-cold T98G-luc/Matrigel suspension (10 µL total volume containing 4×10⁵ cells) is infused at a rate of 1 µL/min over 10 minutes to allow Matrigel polymerization in situ and prevent backflow. A 2-minute dwell period follows before gradual needle retraction. The slow infusion rate is critical for achieving consistent engraftment.
5. Wound Closure and Postoperative Recovery: The burr hole is sealed with bone wax or a biocompatible adhesive, and the scalp is closed with surgical sutures or tissue adhesive. Mice recover on a heated pad until fully ambulatory. Postoperative analgesia (buprenorphine 0.05–0.1 mg/kg) is administered according to IACUC-approved protocols. Body weight and neurologic signs are monitored at least three times weekly using a standardized grading scale (Grade 0–4).
6. Baseline and Longitudinal Bioluminescence Imaging: Beginning 5–7 days post-implantation, mice receive intraperitoneal D-luciferin (150 mg/kg in 100 µL PBS) and are imaged under isoflurane anesthesia using an IVIS Spectrum or equivalent system (acquisition: 30–60 s exposure, binning 4–8, f/stop 1.2). Regions of interest are drawn over the cranial cavity to quantify photon flux (photons/second), enabling weekly tracking of tumor engraftment, growth kinetics, and therapeutic response. Tumors typically become BLI-detectable within 10–14 days and reach peak burden at 4–6 weeks.
7. Therapeutic Intervention and Response Assessment: Once tumors are established (confirmed by consistent BLI signal increase), mice are randomized into treatment and vehicle control cohorts. Given the high MGMT expression and temozolomide-resistant phenotype of T98G, studies may focus on MGMT inhibitors (e.g., O⁶-benzylguanine), DNA repair pathway modulators, PI3K/AKT/mTOR inhibitors, MEK inhibitors, HDAC inhibitors, or BCL-2 family antagonists. Therapeutic agents may be delivered systemically or via intratumoral injection. Response is evaluated through serial BLI, body weight trends, neurologic symptom scores, and Kaplan–Meier survival analysis.
8. Endpoint Analysis and Histopathological Validation: At study termination—defined by ethical endpoints (20% body weight loss, severe neurologic deficits, or predetermined time points)—mice are euthanized. Brains are excised intact, photographed, and processed for formalin-fixed paraffin-embedded sectioning. Coronal sections are stained with H&E for assessment of pseudopalisading necrosis, microvascular proliferation, and perivascular cuffing. Immunohistochemistry is performed for Ki-67 (proliferation index, typically >70% in T98G tumors), GFAP (glial lineage), CD31 (vascularity), MGMT (resistance marker), and cleaved caspase-3 (apoptosis). Tumor volume is quantified by planimetry or digital pathology software.

Fig 2. T98G-luc Orthotopic Mouse Model construction workflow.

Case Study-T98G-luc Orthotopic Mouse Model Development

In a representative preclinical program, the T98G-luc orthotopic model was deployed to evaluate the efficacy of a novel MGMT-targeting small-molecule sensitizer in combination with temozolomide against MGMT-high, temozolomide-resistant glioblastoma. Following Matrigel-assisted stereotactic implantation, tumor engraftment was confirmed by weekly BLI, with photon flux increasing progressively over a 5-week observation window. Mice were randomized at Week 2 into monotherapy and combination arms, with combination-treated animals exhibiting a measurable reduction in bioluminescence signal intensity and delayed neurologic symptom progression relative to temozolomide-alone controls. Postmortem histopathology revealed diminished Ki-67 proliferation indices, attenuated pseudopalisading necrosis, and increased cleaved caspase-3 staining in the combination cohort, alongside reduced MGMT immunoreactivity. These preclinical findings furnished supportive pharmacodynamic and efficacy data to inform subsequent lead optimization and combination regimen design for advanced in vivo pharmacology studies aimed at overcoming alkylating-agent resistance.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your T98G-luc orthotopic glioblastoma program provides access to a specialized preclinical CRO with deep expertise in Matrigel-assisted intracranial xenograft models and resistance-driven oncology study design. Our distinctive strengths include:

• Proven expertise in Matrigel-assisted orthotopic implantation protocols for traditionally non-tumorigenic glioblastoma cell lines, ensuring high engraftment rates and reproducible tumor growth kinetics in immunodeficient hosts.
• Validated T98G-luc cell pools with documented in vitro and in vivo luciferase signal linearity, enabling quantitative, longitudinal bioluminescence tracking from early engraftment through peak tumor burden.
• Specialized capability to design and execute temozolomide-resistance studies leveraging the intrinsic MGMT-high phenotype of T98G, including MGMT inhibitor combination arms, DNA repair pathway modulation, and mechanistic biomarker analysis.
• Integrated small-animal imaging and comprehensive neuropathology services, encompassing BLI, optional MRI, H&E with pseudopalisading necrosis assessment, and IHC panels (Ki-67, GFAP, CD31, MGMT, caspase-3) for multi-dimensional endpoint characterization.
• Flexible study architectures supporting diverse therapeutic classes targeting the PI3K/AKT/mTOR, MEK, HDAC, and BCL-2 survival pathways, with customizable dosing routes, schedules, and combination regimens tailored to your hypothesis.
• Dedicated scientific project management with transparent milestone reporting, real-time data access, and adaptive protocol refinements to align with your regulatory timelines, publication goals, and evolving research priorities.

Contact Us

If your glioblastoma research program requires a translationally relevant, MGMT-expressing orthotopic model for evaluating alkylating-agent resistance and blood-brain barrier–penetrant therapeutics, Alfa Cytology is prepared to advance your preclinical objectives. Reach out to our scientific team to discuss your specific resistance-overcoming strategy, review our T98G-luc model configurations and Matrigel-assisted implantation protocols, and receive a customized study proposal tailored to your timeline and budget. Contact us today to partner with a specialized CRO committed to accelerating your brain cancer discovery pipeline.

For research use only. Not intended for any clinical use.